Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Merck & Co. acquires Rosetta Inpharmatics

11 Jan 2002

Executive Summary

Merck & Co. has acquired Rosetta Inpharmatics (target profiling) in a tax-free stock swap amounting to almost $576mm. Each Rosetta share will be exchanged for 0.24 of a Merck share (or $17.90, an (pr)80% premium based on the market average).
Deal Industry
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Stock

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By